MS4078
Based on 4 publication(s) in Google Scholar
MS4078 is a ALK PROTAC degrader with a DC50 of 11 nM in SU-DHL-1 cells and a DC50 of 59 nM in NCI-H2228 cells, and its Kd value for ALK binding is 19 nM. MS4078 induces ALK degradation via the ubiquitin-proteasome pathway by recruiting cereblon, and inhibits the phosphorylation of ALK and STAT3, thereby suppressing cancer cell proliferation. MS4078 is applicable for the research of non-small cell lung cancer and anaplastic large cell non-Hodgkin's lymphoma.
(Pink: Anaplastic lymphoma kinase (ALK) ligand (HY-15656); Blue: Cereblon ligand (HY-14658); Black: linker).
For research use only. We do not sell to patients.
- Purity : 99.72%
- CAS No.: 2229036-62-6
- Formula: C45H52ClN9O8S
- Molecular Weight:914.47
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
Publications Citing Use of MedChemExpress (MCE) MS4078
MoreAll PROTACs Isoforms
More
Biological Activity
Description
|
ALK 11 nM (DC50, SU-DHL-1 cells) |
ALK 59 nM (DC50, NCI-H2228 cells) |
ALK 19 nM (Kd) |
p-STAT3 |
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| SU-DHL-1 | DC50 |
11 nM
|
Degradation of ALK fusion proteins in human SU-DHL-1 lymphoma cells.
Degradation of ALK fusion proteins in human SU-DHL-1 lymphoma cells.
|
36986673 |
| NCI-H2228 | DC50 |
59 nM
|
Degradation of ALK fusion proteins in human NCI-H2228 lung cancer cells.
Degradation of ALK fusion proteins in human NCI-H2228 lung cancer cells.
|
36986673 |
| SU-DHL-1 | IC50 |
33 nM
|
Inhibition of proliferation in human SU-DHL-1 lymphoma cells.
Inhibition of proliferation in human SU-DHL-1 lymphoma cells.
|
36986673 |
In Vitro
MS4078 (compound 6) binds to DNA-tagged ALK protein with high affinity, with a Kd value of 19 nM[1].
MS4078 (1-100 nM; 16 h) potently degrades the NPM-ALK fusion protein in a concentration-dependent manner, with a DC50 of 11 nM, and inhibits the downstream ALK/STAT3 signaling pathway after 16 hours of treatment in SU-DHL-1 cells[1].
MS4078 (30 nM; 2-24 h) degrades the NPM-ALK fusion protein and inhibits the downstream ALK/STAT3 signaling pathway in SU-DHL-1 cells in a time-dependent manner. At a concentration of 30 nM, its degradation effect peaks at 16 h and persists for at least 24 h[1].
MS4078 (100 nM; 6 h)-induced degradation of the NPM-ALK fusion protein in SU-DHL-1 cells is mediated by a CRBN- and proteasome-dependent mechanism[1].
MS4078 (100 nM; 2 h)-induced degradation of the NPM-ALK fusion protein and the inhibition of downstream signaling pathways in SU-DHL-1 cells are reversible, and these effects diminish 8 h after washout[1].
MS4078 (3-100 nM; 16 h) potently degrades the EML4-ALK fusion protein in a concentration-dependent manner, with a DC50 of 59 nM, and inhibits ALK autophosphorylation in NCI-H2228 cells after 16 hours of treatment[1].
MS4078 (60 nM; 2-24 h) degrades the EML4-ALK fusion protein and inhibits the downstream ALK/STAT3 signaling pathway in a time-dependent manner in NCI-H2228 cells. At a concentration of 60 nM, significant degradation is observed at 8 h, peak degradation occurs at 16 h, and the effect persists for at least 24 h[1].
MS4078 (administered for 3 consecutive days) potently inhibits the proliferation of SU-DHL-1 cells, with an IC50 of 33 nM after 3 days of treatment[1].
MS4078 binds potently to ALK (Kd = 19 nM), degrades ALK fusion proteins in SU-DHL-1 (DC50 =11 nM) and NCI-H2228 (DC50 = 59 nM) cells, and inhibits the proliferation of SU-DHL-1 cells (IC50 = 33 nM)[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:SU-DHL-1 human anaplastic large-cell non-Hodgkin's lymphoma cells expressing NPM-ALK fusion protein
-
Concentration:1, 3, 10, 30, 100 nM
-
Incubation Time:16 h
-
Result:Reduced NPM-ALK fusion protein levels in a concentration-dependent manner, achieving over 90% reduction at 100 nM.
Achieved a DC50 (50% degradation concentration) for NPM-ALK degradation of 11 nM.
Potently inhibited ALK Y1507 phosphorylation and STAT3 Y705 phosphorylation, with over 90% inhibition of both at 100 nM.
-
Cell Line:SU-DHL-1 human anaplastic large-cell non-Hodgkin's lymphoma cells expressing NPM-ALK fusion protein
-
Concentration:30 nM
-
Incubation Time:2, 4, 8, 16, 24 h
-
Result:Inhibited p-ALK and p-STAT3 significantly after 2-hour treatment.
Achieved over 50% NPM-ALK degradation by 4-hour treatment.
Observed maximum NPM-ALK degradation after 16-hour treatment, and both degradation and signaling inhibition were sustained for at least 24 hours.
-
Cell Line:SU-DHL-1 human anaplastic large-cell non-Hodgkin's lymphoma cells expressing NPM-ALK fusion protein
-
Concentration:100 nM
-
Incubation Time:6 h
-
Result:Pre-treatment with pomalidomide, MLN4924, or MG-132 significantly rescued NPM-ALK degradation induced by MS4078, confirming dependency on cereblon (CRBN), cullin RING ligase (CRL) activity, and proteasome function.
-
Cell Line:SU-DHL-1 human anaplastic large-cell non-Hodgkin's lymphoma cells expressing NPM-ALK fusion protein
-
Concentration:100 nM
-
Incubation Time:2 h
-
Result:The effects of MS4078 on NPM-ALK degradation and inhibition of ALK downstream signaling began to diminish at 8 hours after compound removal, confirming reversible degradation activity.
-
Cell Line:NCI-H2228 human non-small-cell lung cancer cells expressing EML4-ALK fusion protein
-
Concentration:3, 10, 30, 60, 100 nM
-
Incubation Time:16 h
-
Result:Reduced EML4-ALK fusion protein levels in a concentration-dependent manner, achieving over 90% reduction at 100 nM.
Achieved a DC50 for EML4-ALK degradation of 59 nM.
Potently and concentration-dependently inhibited ALK auto phosphorylation.
-
Cell Line:NCI-H2228 human non-small-cell lung cancer cells expressing EML4-ALK fusion protein
-
Concentration:60 nM
-
Incubation Time:2, 4, 8, 16, 24 h
-
Result:Observed significant EML4-ALK degradation and ALK signaling inhibition after 8-hour treatment.
Observed maximum EML4-ALK degradation after 16-hour treatment, and both degradation and signaling inhibition were sustained for at least 24 hours.
Parmacokinetics
In Vivo
MS4078 (0.5-10 mg/kg; intravenous, oral; single administration) exhibits moderate in vivo clearance in female CD-1 mice when administered intravenously in a vehicle containing Kolliphor. When administered orally as a Kolliphor-containing solution and an SDD formulation, respectively, the oral bioavailability in mice is low, at 3.5% and 1.3%[2].
MS4078 (50 mg/kg; single dose), an ALK-targeting CRBN-recruiting PROTAC, exhibits favorable in vivo pharmacokinetic properties with excellent plasma exposure and tolerability in mice[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Swiss Albino (male)[1]
-
Dosage:50 mg/kg
-
Administration:i.p.; single dose
-
Result:Achieved peak plasma concentration of 3000 nM at 2 hours post-dosing.
Remained at 340 nM at 12 hours post-dosing.
Was well tolerated with no observable adverse effects.
Chemical Information
-
CAS No. 2229036-62-6
-
Appearance Solid
-
Molecular Weight 914.47
-
Formula C45H52ClN9O8S
-
Color Light yellow to yellow
-
SMILES
CC(C)S(C1=C(NC2=NC(NC3=C(OC(C)C)C=C(C4CCN(CC(NCCNC5=C(C(N(C6C(NC(CC6)=O)=O)C7=O)=O)C7=CC=C5)=O)CC4)C(C)=C3)=NC=C2Cl)C=CC=C1)(=O)=O
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Publications (4)
-
Journal Impact Factor
-
Most Recent
-
Int J Pharm
2024 Jan 25:650:123725. PMID: 38113976 -
Colloids Surf B Biointerfaces
Precision targeting of ALK-positive lung cancer: Engineering HFN@MS4078 nanocages for optimized PROTAC delivery. [Abstract]2025 Jul 22:255:114974. PMID: 40712494 -
Mol Pharm
PROTAC Enabling Formulation In Vivo: Implications of the Polymeric Carrier Eudragit E PO. [Abstract]2025 Aug 24. PMID: 40849796 -
Structure
PROTAC-mediated activation, rather than degradation, of a nuclear receptor reveals complex ligand-receptor interaction network. [Abstract]2024 Dec 5;32(12):2352-2363.e8. PMID: 39389062
Solvent & Solubility
In Vitro:
DMSO : 50 mg/mL (54.68 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
In Vivo:
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: 2.08 mg/mL (2.27 mM); Suspended solution; Need ultrasonic
This protocol yields a suspended solution of 2.08 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Protocols
-
Western Blot
Western blotting (WB) is a commonly used experimental method in molecular biology, biochemistry, and immunogenetics for identifying and quantifying target proteins. It combines gel electrophoresis with immunoassay, enabling researchers to analyze protein expression, post-translational modifications, and molecular weight.
-
BrdU Incorporation Assay
Bromodeoxyuridine (BrdU) incorporation assay is based on the principle that BrdU, a thymidine analog, is incorporated into newly synthesized DNA during the S phase of the cell cycle, thereby serving as a marker of DNA replication and cellular proliferation. Incorporated BrdU can be detected using anti-BrdU antibodies following DNA denaturation, enabling visualization or quantification of proliferating cells through immunochemical detection methods such as immunofluorescence or immunohistochemistry.
-
Somatic Cell Culture
A method of simulating the in vivo environment in vitro to maintain the cell growth, differentation and main functions.
-
CFSE Dye Dilution Proliferation Assay
The CFSE (carboxyfluorescein diacetate succinimidyl ester) dye dilution proliferation assay is based on the covalent labeling of intracellular proteins by a cell-permeant fluorescent dye that becomes fluorescent upon intracellular ester cleavage and then is stably retained within cells. As labeled cells divide, the dye is partitioned equally between daughter cells, resulting in a stepwise halving of fluorescence intensity that can be quantified by flow cytometry to determine the number of cell divisions undergone by each cell population. This fluorescence dilution approach enables quantitative tracking of lymphocyte proliferation at the single-cell level over multiple rounds of division. CFSE-based proliferation analysis has been widely applied to measure antigen-driven lymphocyte expansion in vitro, where discrete fluorescence peaks correspond to successive cell divisions and allow reconstruction of proliferative history within heterogeneous populations.
-
Dye-dilution cell tracking and proliferation staining
Dye-dilution cell tracking assays quantify cell proliferation by covalently labeling intracellular proteins with a stable fluorescent dye that is equally partitioned between daughter cells during mitosis, resulting in stepwise halving of fluorescence intensity with each cell division as measured by flow cytometry histograms. Carboxyfluorescein diacetate succinimidyl ester (CFSE) is a prototypical dye that diffuses into cells, is enzymatically converted into a fluorescent compound, and then covalently binds intracellular amine groups, producing long-lived fluorescence suitable for tracking multiple rounds of division in vitro and in vivo. Successive generations of dividing cells form discrete peaks of decreasing fluorescence intensity, enabling estimation of proliferation history, precursor frequency, and division index within heterogeneous populations. Alternative dyes such as CellTrace Violet (CTV) and far-red membrane dyes (e. g. , PKH26) follow the same dilution principle but differ
-
CCK-8/WST-8 Cell Proliferation Assay
The CCK-8/WST-8 assay is based on the reduction of the water-soluble tetrazolium salt WST-8 to a water-soluble formazan product by cellular dehydrogenases in metabolically active cells, where the generated formazan amount is proportional to the number of living cells and is quantified by measuring absorbance in the visible range, providing a colorimetric readout for cell viability and proliferation assessment. This class of tetrazolium-based assays improves upon earlier MTT-based systems by producing a water-soluble formazan, eliminating the need for organic solubilization steps and enabling direct spectrophotometric measurement in culture medium.
-
Protocol for Cell Cycle
Cell-cycle analysis by flow cytometry measures DNA content in single cells to estimate the fraction of cells in G0/G1, S, and G2/M phases. Propidium iodide intercalates into DNA, and after RNA removal with RNase, fluorescence intensity reflects cellular DNA content: 2N cells are assigned to G0/G1, cells between 2N and 4N to S phase, and 4N cells to G2/M. DNA-content analysis alone cannot reliably separate G0 from G1 or G2 from M. Ki-67 can distinguish quiescent G0 cells from cycling cells, EdU or BrdU incorporation marks active DNA synthesis in S phase, and phospho-histone H3 staining identifies mitotic cells within the 4N population.
-
Cell Counting-Based Growth Curve Assay
Cell counting-based growth curve assays quantify cell proliferation by directly measuring changes in viable cell number over time using manual or automated counting methods such as hemocytometer-based counting or instrument-assisted cell enumeration, enabling construction of growth curves that reflect population expansion dynamics in response to culture conditions. A widely used approach is trypan blue exclusion with hemocytometer counting, where membrane-compromised (non-viable) cells take up the dye, allowing discrimination between viable and non-viable cells while simultaneously enabling total cell number quantification. Repeated sampling across time points allows estimation of proliferation rate, growth phases, and comparative growth kinetics between experimental conditions.
-
Colony Formation (Clonogenic) Assay
The clonogenic (colony formation) assay measures the ability of a single cell to retain reproductive viability and form a macroscopic colony, typically defined as a cluster derived from one progenitor cell after a defined growth period. This assay is widely used to evaluate cell survival after exposure to ionizing radiation or cytotoxic treatments and is considered a standard method in radiation biology for generating dose-response relationships of reproductive cell death. Colony formation reflects long-term proliferative capacity rather than short-term metabolic activity, and survival is quantified by comparing treated versus untreated conditions based on colony number and derived survival fractions.
-
Cell Viability Determination by MTT Colorimetric Assay
The following protocol uses the MTT colorimetric assay as a classic literature-established method for assessing cell viability/metabolic activity in cultured mammalian cells. MTT[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] is reduced by metabolically active cells to a colored formazan product; the amount of formazan is quantified spectrophotometrically and provides an indirect measure of metabolically active viable cells. Importantly, MTT reduction reflects cellular oxidoreductase/metabolic activity rather than an absolute direct count of living cells, so changes in cellular metabolism can alter the signal independently of cell number.
-
Kinase activity and phosphorylation assays
Kinase activity assays measure the ability of kinases to transfer phosphate groups from ATP to specific substrates, while phosphorylation assays detect the presence and levels of phosphorylated proteins. Common methods include radiolabeled ATP incorporation (e. g. ,), ADP release detection via bioluminescence (e. g. ,[3]), enzyme-linked immunosorbent assays (ELISA) for phospho-specific epitopes (e. g. ,[6]), and microtiter-based formats for high-throughput screening (e. g. ,[8]). The ADP-Glo assay quantifies kinase activity by measuring ADP produced during phosphorylation using a luciferase-based system. Radiometric assays involve autoradiography or scintillation counting after incorporation of 32P-labeled ATP into substrate proteins. ELISA-based approaches rely on phospho-specific antibodies to detect activated kinases in cell lysates or purified samples.
-
EdU Incorporation Assay (Click Chemistry-Based DNA Synthesis Measurement)
The EdU incorporation assay measures DNA synthesis by adding the thymidine analog 5-ethynyl-2′-deoxyuridine to cells or tissues, where it is incorporated into newly synthesized DNA during S phase. Incorporated EdU is detected by copper-catalyzed azide-alkyne cycloaddition, in which a fluorescent azide covalently reacts with the ethynyl group on EdU, allowing S-phase cells to be detected by fluorescence microscopy, flow cytometry, or high-content imaging. EdU detection does not require DNA denaturation or anti-BrdU antibody access, which preserves sample structure and improves compatibility with immunostaining and multiparameter cytometry compared with BrdU-based detection. EdU can be cytotoxic in a cell-type- and exposure-dependent manner, so pulse duration, concentration, and continuous-labeling designs should be validated for each cell type.
-
Ki-67 Immunostaining Proliferation Assay
Ki-67 immunostaining measures the growth fraction of a cell population by detecting Ki-67, a nuclear antigen present in proliferating cells and absent in quiescent G0 cells. The readout is the percentage of Ki-67-positive nuclei among total counted cells, commonly called the Ki-67 labeling index or proliferation index.
-
PCNA Immunodetection Proliferation Assay
PCNA immunodetection measures proliferative activity by detecting proliferating cell nuclear antigen, a nuclear protein associated with DNA polymerase δ function and DNA replication. The assay readout is the proportion of PCNA-positive nuclei among total counted cells, but PCNA labeling is not identical to BrdU labeling because PCNA can mark late G1/early S-associated replication competence and may persist beyond active DNA synthesis depending on fixation and extraction conditions.
-
Protocol for Cell Counting and Cell Density Analysis
Cell counting and cell-density analysis estimate the number of cells in a known volume or field area. Manual hemocytometer counting uses a chamber of defined geometry to convert counted cells into cells/mL, while automated counters and image-analysis workflows detect cell objects from optical, brightfield, fluorescence, impedance, or digital-image features. Trypan blue viability counting is based on dye exclusion: viable cells with intact membranes exclude dye, while non-viable cells with compromised membranes stain blue. The readout is total cell density, viable-cell density, dead-cell density, and percent viability. Cell density can also be estimated from microscopy images by counting objects per image area, from flow cytometry using calibrated volume or reference particles, or from in situ microscopy in bioreactors after calibration against reference methods such as hemocytometer or flow cytometry.
-
Protocol for Kinase activity and phosphorylation assays
Kinase activity assays measure transfer of phosphate from ATP to a protein or peptide substrate, generating phosphorylated substrate, ADP, or incorporated radiolabeled phosphate as the readout; phosphorylation assays measure site-specific phosphorylation in cells or tissues as a proxy for kinase-pathway activation, inhibition, or substrate regulation. Phosphorylation can be detected by phospho-specific Western blot, immunoprecipitation kinase assay, phospho-immunofluorescence, phospho-flow cytometry, luminescent ADP detection, radiolabeled ATP incorporation, or reporter-based pathway assays, and these readouts can be applied to cancer cells, primary neurons, mouse tumors, organoids, inflammatory macrophages, ferroptosis studies, and mitophagy studies when the kinase target is biologically relevant.
-
MTT Cell Proliferation Assay
The MTT assay is a colorimetric endpoint assay for estimating viable cell number, cell growth, cytotoxicity, or cell activation in cultured mammalian cells. Living cells reduce the yellow tetrazolium salt MTT into purple/blue formazan, while dead cells do not generate the same signal; the resulting color can be quantified with a multiwell spectrophotometer. MTT reduction is commonly interpreted as a readout of metabolic activity that often correlates with viable cell number, but it should not be treated as a direct cell-counting method unless the assay is optimized for the cell type and experimental condition. Studies show that MTT reduction can involve mitochondrial and non-mitochondrial reducing systems, and formazan may accumulate in intracellular lipid droplets rather than simply marking mitochondria.
Purity & Documentation
-
Data Sheet (290 KB)
-
SDS (394 KB)
- English - EN (394 KB)
- Français - FR (394 KB)
- Deutsch - DE (394 KB)
- Norwegian - NO (394 KB)
- Español - ES (394 KB)
- Swedish - SV (394 KB)
- Italian - IT (394 KB)
- Korean - KR (394 KB)
- Portuguese - PT (394 KB)
-
Handling Instructions (2659 KB)
References
[1]. Zhang C, et al. Proteolysis Targeting Chimeras (PROTACs) of Anaplastic Lymphoma Kinase (ALK). European journal of medicinal chemistry. 2018 May 10;151:304-314. [Content Brief]
[2]. Hofmann N, et al. PROTAC Enabling Formulation : Implications of the Polymeric Carrier Eudragit E PO. Molecular pharmaceutics. 2025 Oct 06;22(10):5845-5859. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.0935 mL | 5.4676 mL | 10.9353 mL | 27.3382 mL |
| 5 mM | 0.2187 mL | 1.0935 mL | 2.1871 mL | 5.4676 mL | |
| 10 mM | 0.1094 mL | 0.5468 mL | 1.0935 mL | 2.7338 mL | |
| 15 mM | 0.0729 mL | 0.3645 mL | 0.7290 mL | 1.8225 mL | |
| 20 mM | 0.0547 mL | 0.2734 mL | 0.5468 mL | 1.3669 mL | |
| 25 mM | 0.0437 mL | 0.2187 mL | 0.4374 mL | 1.0935 mL | |
| 30 mM | 0.0365 mL | 0.1823 mL | 0.3645 mL | 0.9113 mL | |
| 40 mM | 0.0273 mL | 0.1367 mL | 0.2734 mL | 0.6835 mL | |
| 50 mM | 0.0219 mL | 0.1094 mL | 0.2187 mL | 0.5468 mL |
Keywords
- MS4078
- 2229036-62-6
- MS 4078
- MS-4078
- PROTACs
- Anaplastic lymphoma kinase (ALK)
- STAT
- STAT3
- NPM-ALK fusion protein
- anaplastic lymphoma kinase
- human oncogenic active ALK fusion proteins
- non-small cell lung cancer
- EML4-ALK fusion protein
- cereblon
- anaplastic large-cell non-Hodgkin's lymphoma
- NCI-H2228 cells
- SU-DHL-1 cells
- Inhibitor
- inhibitor
- inhibit